{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:14:01Z","timestamp":1768274041932,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Azienda Ospedaliera of Padua"},{"name":"University of Padua","award":["CPDA141311"],"award-info":[{"award-number":["CPDA141311"]}]},{"name":"University of Padua","award":["MURST EX60%"],"award-info":[{"award-number":["MURST EX60%"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jpba.2016.11.032","type":"journal-article","created":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T02:30:42Z","timestamp":1480213842000},"page":"275-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma"],"prefix":"10.1016","volume":"134","author":[{"given":"Giulio","family":"Nannetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Messa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Celegato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio G.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Pal\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.11.032_bib0005","series-title":"World Health Organization Hepatitis C: Fact Sheet No. 164","year":"2016"},{"key":"10.1016\/j.jpba.2016.11.032_bib0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American association for the study of liver diseases. Diagnosis management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","author":"Mauss","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0020","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.26978","article-title":"Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir","volume":"60","author":"Tempestilli","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0025","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/jm401836p","article-title":"Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir","volume":"57","author":"Belema","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2016.11.032_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jpba.2016.11.032_bib0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virol.2014.12.018","article-title":"Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides","volume":"476","author":"Chukkapalli","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0040","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"AASLD-IDSA HCV Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1060028015576180","article-title":"Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients","volume":"49","author":"Burgess","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jpba.2016.11.032_bib0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jpba.2016.11.032_bib0060","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.jchromb.2011.05.036","article-title":"A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma","volume":"879","author":"Jiang","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.11.032_bib0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2012.05.028","article-title":"A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis CNS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine","volume":"1245","author":"Jiang","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2016.11.032_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC\u2013MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.032_bib0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.032_bib0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC\u2013MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.032_bib0085","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"FDA","year":"2013"},{"key":"10.1016\/j.jpba.2016.11.032_bib0090","series-title":"European Medicines Agency Daklinza: Assessment Report","year":"2014"},{"key":"10.1016\/j.jpba.2016.11.032_bib0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jpba.2006.04.031","article-title":"Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection","volume":"42","author":"Loregian","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.032_bib0100","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052 a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2016.11.032_bib0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpba.2016.01.019","article-title":"Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma","volume":"121","author":"Nannetti","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.032_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0140-6736(85)92026-4","article-title":"Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light","volume":"1","author":"Spire","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2016.11.032_bib0115","series-title":"Fields Virology","article-title":"Flaviviridae: the viruses and their replication","author":"Lindenbach","year":"2001"},{"key":"10.1016\/j.jpba.2016.11.032_bib0120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchromb.2007.05.039","article-title":"Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection","volume":"856","author":"Loregian","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.11.032_bib0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijid.2016.06.020","article-title":"Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir and ribavirin","volume":"49","author":"Parisi","year":"2016","journal-title":"Int. J. Infect. Dis."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516305507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516305507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T06:22:37Z","timestamp":1536214957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516305507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":25,"alternative-id":["S0731708516305507"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.11.032","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}